tcr

α-Galactosylceramide (KRN7000) is a synthetic glycolipid with antitumorial and immunostimulatory and is a very potent NKT cell agonist and binds effectively to CD1d. The complex of α-Galactosylceramide and CD1d can bind to the T cell antigen receptor of NKT cells.

TCR-IN-1 (Compound A-33) is an inhibitor of TCR. It effectively blocks the release of cytokines (IL-2, TNFα, IFNγ, IL-17A).

TCR-IN-2 (Compound A-68) is a TCR inhibitor that suppresses the release of IFNγ and IL-2. It also inhibits the time-dependent phosphorylation of CD3ζ and prevents TCR-mediated T cell activation, whether under anti-CD3 antibody stimulation or stimulation by HLA mismatched human cells.

Anti-Mouse TCR gamma/delta Antibody is an IgG class inhibitor derived from the host Armenian Hamster, targeting the mouse TCR gamma/delta receptor.

Anti-Mouse TCR V gamma 2 Antibody is an inhibitory IgG antibody derived from Armenian Hamster, targeting mouse TCR V gamma 2.

Anti-Mouse Vβ8 TCR Antibody (F23.1) is an IgG2a, κ antibody inhibitor derived from mice, targeting mouse Vβ8 TCR.

Anti-Mouse 2C TCR Antibody (1B2) is an IgG1 antibody inhibitor derived from mice, specifically targeting the mouse 2C TCR.

Anti-Rat TCR alpha/beta Antibody (R73) is an IgG1, κ antibody inhibitor derived from mice, targeting rat TCR α/beta.

Anti-Rat TCR gamma/delta Antibody (V65) is an IgG1, κ antibody inhibitor derived from mice, targeting rat TCR γ/δ.

Anti-Mouse Vβ4 TCR Antibody (KT4) is an IgG2b inhibitor antibody of rat origin that targets the mouse Vβ4 TCR.

Anti-Mouse TCR Vγ1.1/Cr4 Antibody (2.11) is an IgG antibody inhibitor derived from the U.S. hamster, targeting mouse TCR Vγ1.1/Cr4.

Anti-TCR Antibody (NKTT320) represents a highly specialized humanized agonistic monoclonal antibody specifically engineered to target the invariant T-cell receptor of iNKT cells with exceptional binding affinity and selectivity, effectively facilitating the measurable activation and expansion of this unique lymphocyte subset across various preclinical experimental models to evaluate the induction of immunomodulatory cytokines during strictly monitored laboratory observation periods.

Anti-Mouse TCR Beta Antibody (H57-597) is an antibody targeting TCR Beta and can be used for immunology research.

Anti-Mouse TCRβ Antibody (HB218) is an IgG antibody inhibitor derived from American hamster, specifically targeting mouse TCRβ.

TCRS-417 (T417) inhibits PBX1-DNA interaction in mammalian cells or cell clusters, used in autoimmune and neurodegenerative disease research.

Lagociclovir (MIV-210), a nucleoside analogue, is an antiviral compound available for the treatment of HBV82 that inhibits the replication of wild-type hepatitis B virus (HBV) in human hepatocellular carcinoma cell lines that permanently express HBV.

IHVR-17028 is a potent broad-spectrum ERα-glucosidase I (α-glucosidase I) inhibitor with IC50 of 0.24 μM and antiviral activity. IHVR-17028 inhibited BVDV, TCRV and DENV, and EC50 values were 0.4 μM, 0.26 μM and 0.3 μM, respectively. IHVR-17028 can be used to study infectious diseases.

T.cruzi Inhibitor hydrochloride is a Trypanosoma cruzi inhibitor.

DST crosslinker(disuccinimide tartarate) is an isotype bifunctional, cleavable crosslinker (cleavable by an oxidizer) for applications that require crosslinking cleavability and that do not interfere with protein disulfide bonds with reducing agents.

(S)-crizotinib (ent-crizotinib) （IC50 of 72 nM）, an effective MTH1 (NUDT1) inhibitor, is the (S)-enantiomer of crizotinib.

PI3K/Akt/CREB activator 1 (AE-18) is a selective inducible nitric oxide synthase (iNOS) inhibitor that crosses the blood-brain barrier, reduces infarct size and restores blood supply deficits after ischemia-reperfusion in rats, and is used in studies of vascular dementia and Parkinson's disease.

Urocortin, rat TFA is a neuropeptide and a potent endogenous CRFR agonist (Kis: 0.97 nM, 1.5 nM, and 13 nM for mouse CRF2β, rat CRF2α, and human CRF1).

KRM-III is an orally active T cell antigen receptor (TCR) inhibitor with anti-inflammatory activity that potently inhibits TCR and myristate acetate/fosfomycin/ionomycin-induced NFAT nuclear factor activation and T cell proliferation, with an IC50 of approximately 5 μM.

PF-07265028 is a highly potent and selective small-molecule inhibitor of hematopoietic progenitor cell kinase 1 (HPK1/MAP4K1). By blocking HPK1-mediated signal transduction, PF-07265028 enhances T-cell receptor-associated signaling, thereby lifting immune suppression and promoting antitumor immune responses. PF-07265028 exhibits significant activity at the cellular level (e.g., inhibition of pSLP76, IC₅₀ approximately 17 nM). PF-07265028 is suitable for use in cancer research.